These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome. Helbig G; Kyrcz-Krzemień S Am J Hematol; 2014 Jan; 89(1):115. PubMed ID: 24009127 [No Abstract] [Full Text] [Related]
4. Rapid reversion of eosinophilic gastroenteritis associated with FIP1L1-PDGFRA fusion after targeted therapy with imatinib. Pitini V; Sturniolo G; Cavallari V; Arrigo C Br J Haematol; 2006 Jan; 132(2):123. PubMed ID: 16398645 [No Abstract] [Full Text] [Related]
5. [FIP1L1-PDGFRalpha-positive myeloproliferative disease with hypereosinophilia: clinical characteristics and pathogenetic therapy]. Nemchenko IS; Khoroshko ND; Turkina AG; Sokolova MA; Kokhno AV; Semenova EA; Zakharova AV Ter Arkh; 2005; 77(7):90-2. PubMed ID: 16116920 [No Abstract] [Full Text] [Related]
6. Imatinib Treatment of Lymphomatoid Papulosis Associated with Myeloproliferative Hypereosinophilic Syndrome Presenting the FIP1L1-PDGFRA Fusion Gene. García-Martínez P; Sitjas D; Llistosella E; Espinet B; Rodríguez-Rivera M; Hernandez-Muñoz M; Gallardo F; Pujol RM Acta Derm Venereol; 2017 Jul; 97(7):855-857. PubMed ID: 28374041 [No Abstract] [Full Text] [Related]
7. The hypereosinophilic syndrome: idiopathic or not, that is the question. Cools J Haematologica; 2005 May; 90(5):582-4. PubMed ID: 15921372 [No Abstract] [Full Text] [Related]
8. Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders. Pardanani A; Tefferi A Leuk Res; 2004 May; 28 Suppl 1():S47-52. PubMed ID: 15036941 [TBL] [Abstract][Full Text] [Related]
9. An imatinib-treated FIL1P1-PDGFRα chronic eosinophilic leukemia transforming to erythroid blast crisis: a case report. Papanikolaou X; Kotsopoulou M; Triantafillopoulou ID; Zoi A; Chatziantoniou V; Maltezas D; Mitsouli-Mentzikof C Ann Hematol; 2012 May; 91(5):785-787. PubMed ID: 21881824 [No Abstract] [Full Text] [Related]
10. Detection of FIP1L1-PDGFRA fusion by FISH. Ma ES; Wong KF; Wong CL; Siu LL Br J Haematol; 2007 Aug; 138(3):279. PubMed ID: 17542982 [No Abstract] [Full Text] [Related]
11. Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study. Metzgeroth G; Walz C; Erben P; Popp H; Schmitt-Graeff A; Haferlach C; Fabarius A; Schnittger S; Grimwade D; Cross NC; Hehlmann R; Hochhaus A; Reiter A Br J Haematol; 2008 Dec; 143(5):707-15. PubMed ID: 18950453 [TBL] [Abstract][Full Text] [Related]
15. Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-a positive idiopathic hypereosinophilic syndrome. Martinelli G; Malagola M; Ottaviani E; Rosti G; Trabacchi E; Baccarani M Haematologica; 2004 Feb; 89(2):236-7. PubMed ID: 15003901 [No Abstract] [Full Text] [Related]
16. [Efficacy of imatinib in FIP1L1-PDGFRA positive hypereosinophilic syndrome]. Menif S; Ben Romdhane N; Hafsia R Rev Med Interne; 2008 Jan; 29(1):65-7. PubMed ID: 18036706 [TBL] [Abstract][Full Text] [Related]
17. A case of hypereosinophilic syndrome presenting with chronic cough successfully treated with imatinib. Kobayashi M; Kubota T; Uemura Y; Taguchi H Respirology; 2009 Mar; 14(2):302-4. PubMed ID: 19192229 [TBL] [Abstract][Full Text] [Related]